Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 211

1.

Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study.

Stubendorff K, Larsson V, Ballard C, Minthon L, Aarsland D, Londos E.

BMJ Open. 2014 Jul 3;4(7):e005158. doi: 10.1136/bmjopen-2014-005158.

PMID:
24993765
[PubMed]
Free PMC Article
2.

Risk Factors That Affect Life Expectancy in Alzheimer's Disease: A 15-Year Follow-Up.

Wattmo C, Londos E, Minthon L.

Dement Geriatr Cogn Disord. 2014 Jul 3;38(5-6):286-299. [Epub ahead of print]

PMID:
24992891
[PubMed - as supplied by publisher]
3.

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease.

Hansson O, Hall S, Ohrfelt A, Zetterberg H, Blennow K, Minthon L, Nägga K, Londos E, Varghese S, Majbour NK, Al-Hayani A, El-Agnaf OM.

Alzheimers Res Ther. 2014 May 7;6(3):25. doi: 10.1186/alzrt255. eCollection 2014.

PMID:
24987465
[PubMed]
Free PMC Article
4.

Involvement of Matrix Metalloproteinase-9 in Amyloid-β 1-42-Induced Shedding of the Pericyte Proteoglycan NG2.

Schultz N, Nielsen HM, Minthon L, Wennström M.

J Neuropathol Exp Neurol. 2014 Jul;73(7):684-92. doi: 10.1097/NEN.0000000000000084.

PMID:
24918635
[PubMed - in process]
Free PMC Article
5.

Kynurenic Acid levels in cerebrospinal fluid from patients with Alzheimer's disease or dementia with lewy bodies.

Wennström M, Nielsen HM, Orhan F, Londos E, Minthon L, Erhardt S.

Int J Tryptophan Res. 2014 Apr 28;7:1-7. doi: 10.4137/IJTR.S13958. eCollection 2014.

PMID:
24855376
[PubMed]
Free PMC Article
6.

Lack of orthostatic symptoms in dementia patients with orthostatic hypotension.

Bengtsson-Lindberg M, Larsson V, Minthon L, Wattmo C, Londos E.

Clin Auton Res. 2014 Apr 18. [Epub ahead of print]

PMID:
24743866
[PubMed - as supplied by publisher]
7.

The cerebrospinal fluid "Alzheimer profile": Easily said, but what does it mean?

Duits FH, Teunissen CE, Bouwman FH, Visser PJ, Mattsson N, Zetterberg H, Blennow K, Hansson O, Minthon L, Andreasen N, Marcusson J, Wallin A, Rikkert MO, Tsolaki M, Parnetti L, Herukka SK, Hampel H, De Leon MJ, Schröder J, Aarsland D, Blankenstein MA, Scheltens P, van der Flier WM.

Alzheimers Dement. 2014 Apr 7. pii: S1552-5260(14)00029-6. doi: 10.1016/j.jalz.2013.12.023. [Epub ahead of print]

PMID:
24721526
[PubMed - as supplied by publisher]
8.

Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer's disease: an observational study.

Hertze J, Nägga K, Minthon L, Hansson O.

BMC Neurol. 2014 Apr 1;14:64. doi: 10.1186/1471-2377-14-64.

PMID:
24685003
[PubMed - in process]
Free PMC Article
9.

Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.

Martínez-Morillo E, Hansson O, Atagi Y, Bu G, Minthon L, Diamandis EP, Nielsen HM.

Acta Neuropathol. 2014 May;127(5):633-43. doi: 10.1007/s00401-014-1266-2. Epub 2014 Mar 15.

PMID:
24633805
[PubMed - in process]
10.

Low levels of soluble NG2 in cerebrospinal fluid from patients with dementia with Lewy bodies.

Nielsen HM, Hall S, Surova Y, Nägga K, Nilsson C, Londos E, Minthon L, Hansson O, Wennström M.

J Alzheimers Dis. 2014;40(2):343-50. doi: 10.3233/JAD-132246.

PMID:
24448788
[PubMed - in process]
11.

Assessment of peptide chemical modifications on the development of an accurate and precise multiplex selected reaction monitoring assay for apolipoprotein e isoforms.

Martínez-Morillo E, Nielsen HM, Batruch I, Drabovich AP, Begcevic I, Lopez MF, Minthon L, Bu G, Mattsson N, Portelius E, Hansson O, Diamandis EP.

J Proteome Res. 2014 Feb 7;13(2):1077-87. doi: 10.1021/pr401060x. Epub 2014 Jan 14.

PMID:
24392642
[PubMed - in process]
12.

[In Process Citation].

Nägga K, Minthon L, Eriksdotter M.

Lakartidningen. 2013 Nov 6-12;110(45):1996-9. Swedish. No abstract available.

PMID:
24364185
[PubMed - in process]
13.

NG2 cells, a new trail for Alzheimer's disease mechanisms?

Nielsen HM, Ek D, Avdic U, Orbjörn C, Hansson O; Netherlands Brain Bank, Veerhuis R, Rozemuller AJ, Brun A, Minthon L, Wennström M.

Acta Neuropathol Commun. 2013 May 9;1(1):7. doi: 10.1186/2051-5960-1-7.

PMID:
24252600
[PubMed]
Free PMC Article
14.

Multidisciplinary intervention reducing readmissions in medical inpatients: a prospective, non-randomized study.

Torisson G, Minthon L, Stavenow L, Londos E.

Clin Interv Aging. 2013;8:1295-304. doi: 10.2147/CIA.S49133. Epub 2013 Sep 26.

PMID:
24106422
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Progression of mild Alzheimer's disease: knowledge and prediction models required for future treatment strategies.

Wattmo C, Wallin AK, Minthon L.

Alzheimers Res Ther. 2013 Oct 7;5(5):44. doi: 10.1186/alzrt210. eCollection 2013.

PMID:
24099236
[PubMed]
Free PMC Article
16.

Automatic temporal lobe atrophy assessment in prodromal AD: Data from the DESCRIPA study.

Chincarini A, Bosco P, Gemme G, Esposito M, Rei L, Squarcia S, Bellotti R, Minthon L, Frisoni G, Scheltens P, Frölich L, Soininen H, Visser PJ, Nobili F; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2014 Jul;10(4):456-67. doi: 10.1016/j.jalz.2013.05.1774. Epub 2013 Sep 12.

PMID:
24035058
[PubMed - in process]
17.

Evaluation of the cerebrospinal fluid amyloid-β1-42/amyloid-β1-40 ratio measured by alpha-LISA to distinguish Alzheimer's disease from other dementia disorders.

Nutu M, Zetterberg H, Londos E, Minthon L, Nägga K, Blennow K, Hansson O, Ohrfelt A.

Dement Geriatr Cogn Disord. 2013;36(1-2):99-110. doi: 10.1159/000353442. Epub 2013 Jul 9.

PMID:
23860354
[PubMed - indexed for MEDLINE]
18.

Evaluating amyloid-β oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease.

Hölttä M, Hansson O, Andreasson U, Hertze J, Minthon L, Nägga K, Andreasen N, Zetterberg H, Blennow K.

PLoS One. 2013 Jun 14;8(6):e66381. doi: 10.1371/journal.pone.0066381. Print 2013.

PMID:
23799095
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Tau pathology and parietal white matter lesions have independent but synergistic effects on early development of Alzheimer's disease.

Hertze J, Palmqvist S, Minthon L, Hansson O.

Dement Geriatr Cogn Dis Extra. 2013 Apr 19;3(1):113-22. doi: 10.1159/000348353. Print 2013 Jan.

PMID:
23687506
[PubMed]
Free PMC Article
20.

A longitudinal study of risk factors for community-based home help services in Alzheimer's disease: the influence of cholinesterase inhibitor therapy.

Wattmo C, Paulsson E, Minthon L, Londos E.

Clin Interv Aging. 2013;8:329-39. doi: 10.2147/CIA.S40087. Epub 2013 Mar 20.

PMID:
23682212
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk